Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase for dysfunctional hemodialysis catheters
NCT00396032Phase 3Completed
- Sponsor
- Genentech
- Start
- Oct 2006
- Primary completion
- Dec 2008
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 3, randomised, double-blind trial in catheter dysfunction comparing Tenecteplase with Placebo (2 arms). Primary endpoints: Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 and Incidence of Targeted Adverse Events (AEs) From Initial Study Drug Administration Through the Start of Visit 2. Started Oct 2006; status: completed.
02
Drugs
tenecteplase
03
Conditions
catheter dysfunction
Beyond the preview
Go deeper on NCT00396032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396032.